Curis, Inc. And Wyeth Extend Nerve Drug Pact

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2005--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that Wyeth has exercised its option under the 2004 agreement to extend funding to continue development of therapeutic applications of the Hedgehog agonist with a primary focus on neurological disorders. By exercising this option, Wyeth has agreed to extend the research term by one year through February 9, 2007 (previously February 9, 2006). Curis expects Wyeth to select a development candidate in the next twelve to eighteen months, and to file an investigational new drug, or IND, application approximately twelve months thereafter.